File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comprehensive management of hepatocellular carcinoma

TitleComprehensive management of hepatocellular carcinoma
肝癌的综合治疗
Authors
KeywordsLiver neoplasms
Hepatectomy
Liver transplantation
Transarterial chemoembolization
Molecular targeted therapy
Issue Date2011
Publisher中华消化外科杂志社中華醫學會. The Journal's web site is located at http://zhxhwk.swhospital.com/
Citation
中华消化外科杂志, 2011, v. 10 n. 4, p. 241-246 How to Cite?
Chinese Journal of Digestive Surgery, 2011, v. 10 n. 4, p. 241-246 How to Cite?
AbstractHepatocellular carcinoma(HCC)is nowadays one of the leading common causes of cancer death and mostly occurs in hepatitis B endemic areas.Typically,HCC patients presented late and only about 20% of the patients are amendable to surgical interventions.Surgical resection is the main curative treatment option.Nevertheless,the recurrence rate after potential curative liver resection is still very high.On the other hand,liver transplantation is the treatment of choice for early small HCC but its application is limited by the availability of liver grafts.Radiofrequency ablation is more commonly used in cirrhotic patients with small tumours who are not surgical candidates.Nowadays,transarterial chemoembolisation,drugeluting bead transarterial chemoembolisation and radioembolisation are the mainstay of treatments for the patients with intermediate HCC.Other systemic approaches,such as hormonal therapy,immunotherapy and chemotherapy have disappointing results.In particular,HCC is highly refractory to cytotoxic chemotherapy.This is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients.Recently,encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients.Similar to sorafenib,other anti-angiogenic multi-targeted tyrosine kinase inhibitors,such as pazopanib,brivanib and axitinib also show promising activity in various stages of clinical trials.There is an urgent need to identify biomarkers that may guide the rational use of sorafenib and other targeted agents in the era of personalised medicine.More importantly,the multidisciplinary model in managing HCC patients is the important key to the future success.
Persistent Identifierhttp://hdl.handle.net/10722/159914
ISSN

 

DC FieldValueLanguage
dc.contributor.authorFan, STen_US
dc.contributor.authorYau, TCCen_US
dc.contributor.authorPoon, RTPen_US
dc.date.accessioned2012-08-16T05:59:29Z-
dc.date.available2012-08-16T05:59:29Z-
dc.date.issued2011en_US
dc.identifier.citation中华消化外科杂志, 2011, v. 10 n. 4, p. 241-246en_US
dc.identifier.citationChinese Journal of Digestive Surgery, 2011, v. 10 n. 4, p. 241-246-
dc.identifier.issn1673-9752-
dc.identifier.urihttp://hdl.handle.net/10722/159914-
dc.description.abstractHepatocellular carcinoma(HCC)is nowadays one of the leading common causes of cancer death and mostly occurs in hepatitis B endemic areas.Typically,HCC patients presented late and only about 20% of the patients are amendable to surgical interventions.Surgical resection is the main curative treatment option.Nevertheless,the recurrence rate after potential curative liver resection is still very high.On the other hand,liver transplantation is the treatment of choice for early small HCC but its application is limited by the availability of liver grafts.Radiofrequency ablation is more commonly used in cirrhotic patients with small tumours who are not surgical candidates.Nowadays,transarterial chemoembolisation,drugeluting bead transarterial chemoembolisation and radioembolisation are the mainstay of treatments for the patients with intermediate HCC.Other systemic approaches,such as hormonal therapy,immunotherapy and chemotherapy have disappointing results.In particular,HCC is highly refractory to cytotoxic chemotherapy.This is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients.Recently,encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients.Similar to sorafenib,other anti-angiogenic multi-targeted tyrosine kinase inhibitors,such as pazopanib,brivanib and axitinib also show promising activity in various stages of clinical trials.There is an urgent need to identify biomarkers that may guide the rational use of sorafenib and other targeted agents in the era of personalised medicine.More importantly,the multidisciplinary model in managing HCC patients is the important key to the future success.-
dc.languagechien_US
dc.publisher中华消化外科杂志社中華醫學會. The Journal's web site is located at http://zhxhwk.swhospital.com/-
dc.relation.ispartof中华消化外科杂志en_US
dc.relation.ispartofChinese Journal of Digestive Surgery-
dc.subjectLiver neoplasms-
dc.subjectHepatectomy-
dc.subjectLiver transplantation-
dc.subjectTransarterial chemoembolization-
dc.subjectMolecular targeted therapy-
dc.titleComprehensive management of hepatocellular carcinomaen_US
dc.title肝癌的综合治疗-
dc.typeArticleen_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.emailYau, TCC: tyaucc@hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.authorityYau, TCC=rp01466en_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.identifier.doi10.3760/cma.j.issn.1673-9752.2011.04.001-
dc.identifier.hkuros202617en_US
dc.identifier.hkuros204255-
dc.identifier.volume10en_US
dc.identifier.issue4en_US
dc.identifier.spage241en_US
dc.identifier.epage246en_US
dc.publisher.placeChina-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats